The New England journal of medicine
-
After promising initial results from the administration of a third (booster) dose of the BNT162b2 messenger RNA vaccine (Pfizer-BioNTech) to persons 60 years of age or older, the booster campaign in Israel was gradually expanded to persons in younger age groups who had received a second dose at least 5 months earlier. ⋯ Across the age groups studied, rates of confirmed Covid-19 and severe illness were substantially lower among participants who received a booster dose of the BNT162b2 vaccine than among those who did not.
-
Letter Comparative Study
Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections.
-
Letter Comparative Study
Viral Dynamics of SARS-CoV-2 Variants in Vaccinated and Unvaccinated Persons.